Elicio Therapeutics CEO and leadership

Robert Connelly is a prolific entrepreneur and leader with more than 30 years of experience in the life science industry and close to 20 years as a CEO building startup and early stage novel therapeutic platform companies. He was the founding CEO and first employee of Domantis, which sold to GlaxoSmithKline in 2007 for $454 million, and served as CEO of Pulmatrix (NASDAQ: PULM) and Axcella Health, as well as Chairman or Director on numerous Boards of Directors. During his tenures as a CEO, Mr. Connelly has raised over $300 million in private equity financing. He has also led numerous partnering transactions for his companies, including product and platform licensing, government and foundation funding, and M&A transactions, while launching innovative platforms and products across disease areas. Mr. Connelly also serves as a director for Anchiano Therapeutics (NASDAQ: ANCH) and was previously a Venture Partner with Flagship Pioneering, serving on the Boards of Kaleido Biosciences (NASDAQ:KLDO) and Kintai Therapeutics. Mr. Connelly began his career at Abbott Laboratories spending 11 years in sales, marketing and management positions of increasing responsibility.

Dr. Christopher Haqq joined Atara Biotherapeutics as Chief Medical Officer in 2012. He brings 20 years of clinical, academic and drug development experience from biopharma companies large and small. He was recently Vice President for Clinical Research and Development at Cougar Biotechnology and Janssen, where he was the lead clinician for a pivotal prostate cancer study leading to market approval for Zytiga® (abiraterone acetate). Previously at Amgen, he led early development studies of the anti-insulin like growth factor type 1 receptor AMG 479 (ganitumab) antibody. He has served as medical monitor for more than 10 clinical trials and has contributed to drug development programs for a wide range of molecules. Chris has worked closely with the European Medicines Agency, the US Food and Drug Administration and other global regulatory agencies–filing investigational new drug applications, new drug applications, special protocol assessments and their international equivalents. Earlier in his career, Chris practiced as a medical oncologist and led a translational science laboratory as an Assistant Professor in the Division of Hematology/Oncology at the University of California, San Francisco. In his post-graduate training, also at UCSF, he served as an Intern and Resident in Internal Medicine, Fellow in Medical Oncology and Fellow in Molecular Medicine. Chris completed his M.D. and Ph.D. in Genetics at Harvard Medical School and his undergraduate training at Stanford University and the University of British Columbia. He is board certified in Medical Oncology and Internal Medicine. Chris is an inventor of three patents and an author of nearly 50 medical publications. In his free time, he enjoys astronomy and photography.

Daniel Geffken has served as a member of the Windtree Board of Directors since April 2019. He serves as Chairman of the Board’s Audit Committee and is a member of the Compensation Committee. Mr. Geffken has more than 30 years of financial management experience to the board, ranging from start-ups to publicly traded companies with over $1 billion market capitalizations. Since 2011, Mr. Geffken has been serving as the Founding Managing Partner of Danforth Advisors, a leading financial and strategy consulting firm to the life sciences industry. He has also served as chief financial officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Cabaletta Bio, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Mr. Geffken has served on the Board of Directors of Elicio Bio, Alcobra Ltd. and Arcturus Inc., after its merger with Alcobra. Since 2013, he has assisted in ten initial public offering filings. Over the course of his career, he has assisted in raising more than $1 billion in equity and debt securities for life science companies.

Daniel holds a BS from The Wharton School, University of Pennsylvania, and an MBA from Harvard Business School.

Robert Connelly is a prolific entrepreneur and leader with more than 30 years of experience in the life science industry and close to 20 years as a CEO building startup and early stage novel therapeutic platform companies. He was the founding CEO and first employee of Domantis, which sold to GlaxoSmithKline in 2007 for $454 million, and served as CEO of Pulmatrix (NASDAQ: PULM) and Axcella Health, as well as Chairman or Director on numerous Boards of Directors. During his tenures as a CEO, Mr. Connelly has raised over $300 million in private equity financing. He has also led numerous partnering transactions for his companies, including product and platform licensing, government and foundation funding, and M&A transactions, while launching innovative platforms and products across disease areas. Mr. Connelly also serves as a director for Anchiano Therapeutics (NASDAQ: ANCH) and was previously a Venture Partner with Flagship Pioneering, serving on the Boards of Kaleido Biosciences (NASDAQ:KLDO) and Kintai Therapeutics. Mr. Connelly began his career at Abbott Laboratories spending 11 years in sales, marketing and management positions of increasing responsibility.

Daniel Geffken has served as a member of the Windtree Board of Directors since April 2019. He serves as Chairman of the Board’s Audit Committee and is a member of the Compensation Committee. Mr. Geffken has more than 30 years of financial management experience to the board, ranging from start-ups to publicly traded companies with over $1 billion market capitalizations. Since 2011, Mr. Geffken has been serving as the Founding Managing Partner of Danforth Advisors, a leading financial and strategy consulting firm to the life sciences industry. He has also served as chief financial officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Cabaletta Bio, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Mr. Geffken has served on the Board of Directors of Elicio Bio, Alcobra Ltd. and Arcturus Inc., after its merger with Alcobra. Since 2013, he has assisted in ten initial public offering filings. Over the course of his career, he has assisted in raising more than $1 billion in equity and debt securities for life science companies.

Daniel holds a BS from The Wharton School, University of Pennsylvania, and an MBA from Harvard Business School.